Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MBRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMoleculin Biotech reports Q1 2026 financial results and operational updates
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
medium
Company disclosed financial results for the quarter ended March 31, 2026, along with recent operational highlights. Specific figures and details are contained in the attached press release.
Item 2.02 verify on EDGAR → -
medium
This is a routine quarterly earnings disclosure filed via 8-K. The filing body contains no financial details; investors should review the full press release for actual results and operational updates.
8-K: Earnings view on EDGAR →
Summary
Moleculin Biotech filed an 8-K to announce its first quarter 2026 financial results for the period ending March 31, 2026. This is a standard quarterly earnings disclosure, with the company issuing a press release on May 15, 2026, that includes both financial figures and operational highlights. The 8-K filing itself contains no specific financial data or operational details in its body text.
For retail investors, this represents routine quarterly reporting. The actual substance of the disclosure—revenue, expenses, cash position, clinical trial progress, or other operational developments—is contained in the attached press release, which is not included in the 8-K body. Investors should review the full press release to assess the company's financial health and progress on its drug development programs. Watch for any updates on clinical trial timelines or cash runway in the detailed press release.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 15, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and recent operational highlights.
The company announced financial results for the first quarter of 2026 ending March 31, 2026, along with operational highlights. The actual financial figures and operational details are contained in the attached press release (Exhibit 99.1), which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Moleculin Biotech filed an 8-K attaching a press release dated May 15, 2026; no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release dated May 15, 2026
The 8-K references an attached press release dated May 15, 2026. The filing body provides no details about the press release content, so the nature and materiality of the disclosure cannot be determined from this 8-K alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 26, 2026 · How we verify